Brought to you by:
-
best medical therapy, carotid artery disease, carotid artery stenting, CEA, CREST-2, NEJM, VEITH 2025
‘Historical’ CREST-2 data show reduced stroke risk with carotid stenting versus medical therapy alone
The international CREST-2 study has found that, for people with severe carotid artery narrowing who have not experienced recent stroke symptoms, a minimally invasive carotid artery stenting (CAS) procedure—combined with intensive medical therapy—significantly lowered stroke risk compared with medical therapy alone. The more traditional surgical approach of carotid endarterectomy (CEA) did not show the same…
-
Atherectomy in PAD: Meta-analysis of ‘extensive’ published literature supports use in ‘appropriately selected’ patients
A systematic review and meta-analysis of more than 300 original investigations on atherectomy in peripheral arterial disease (PAD) highlights “overall favorable” clinical outcomes. This and other findings from what researchers say is the first investigation to provide a “comprehensive” overview of the atherectomy literature were recently published in the Journal of the Society for Cardiovascular…
-
‘We need to look at the totality of evidence’: VIVA panelists examine SWEDEPAD findings
A focused session at the 2025 Vascular Interventional Advances (VIVA) conference (2–5 November, Las Vegas, USA) homed in on the latest findings from the SWEDEPAD registry-based randomized controlled trials (RCTs), with panelists discussing the results with reference to the wider evidence base on drug-coated device use in peripheral arterial disease (PAD). Joakim Nordanstig (University of Gothenburg, Gothenburg,…
-
chronic venous insufficiency, Envveno Medical, ESVS 2025, European Society for Vascular Surgery, Venous disease, venous valve, VenoValve, Western Vascular Society, WVS 2025
Chronic venous insufficiency: Appeal over ‘not-approvable’ VenoValve fails
enVVeno Medical has announced that it received an “unfavorable” decision from the Food & Drug Administration (FDA) in response to its supervisory appeal of the “not-approvable” letter it received on Aug. 19 in response to its premarket approval (PMA) application for the VenoValve device, a surgical replacement venous valve for treating severe deep chronic venous…
-
PROMISE III: Six-month data ‘reinforce’ case for TADV in no-option CLTI patients
Six-month outcomes among no-option chronic limb-threatening ischemia (CLTI) patients treated using transcatheter arterialization of the deep veins with the LimFlow system (Stryker/Inari Medical) in the PROMISE III trial showed a 81% rate of amputation-free survival. Principal investigator Daniel Clair, MD, chair of vascular surgery at Vanderbilt University in Nashville, Tennessee, delivered the primary safety endpoint…
-
PERFORMANCE III demonstrates ‘very low’ 30-day event rates for dual neuroprotection in TCAR
Thirty-day results from the PERFORMANCE III study of integrated embolic protection (IEP) in transcarotid artery revascularization (TCAR) demonstrate “very low” 30-day event rates. Sean Lyden, MD, chair of vascular surgery at the Cleveland Clinic in Cleveland, Ohio, shared this finding during a late-breaking trials session at the 2025 Vascular Interventional Advances (VIVA) conference (Nov. 2–5)…
-
‘Excellent’ one-year outcomes from ROADSTER 3 show TCAR is ‘safe and effective’
One-year outcomes in the ROADSTER 3 post-approval study to evaluate the safety and effectiveness of transcarotid artery revascularization (TCAR) using the Enroute stent and neuroprotection system (Boston Scientific) in standard-surgical-risk patients revealed a 1.5% intention-to-treat rate of composite major adverse events (1.3% per protocol). Delivering the results at the 2025 Vascular Interventional Advances (VIVA) conference (2–5 November,…
-
Vein mapping rates show no sign of change two years after BEST-CLI, new study demonstrates
Vein mapping for lower extremity bypass in patients with chronic limb-threatening ischemia (CLTI) remains unchanged two years after the BEST-CLI, “revealing the difficulty in changing practice patterns based on new evidence,” according to the authors behind a new retrospective multicenter study analyzing vein mapping performance before and after the landmark trial. First results from the…
-
SVS receives slew of VAM 2026 ‘Hot Topics’ session proposals
Proposals for the new “Hot Topics” session at the 2026 Vascular Annual Meeting (VAM) recently drew in a slew of responses for the inaugural iteration of the program feature. Hot Topics sessions are designed to feature short, high-impact presentations on emerging issues, innovations and practice-changing developments in vascular surgery. Each proposal required an outline of…
-
‘Ask not what vascular surgery can do for you… ask what it can do to you’
During his own recent presidential address on home turf, Patrick Muck, MD, invoked immortable words from the inaugural address of President John F. Kennedy to make a very serious point about radiation safety in vascular care: “Ask not what vascular surgery can do for you… ask what it can do to you.” Muck said that…